|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C显示文摘 | Bruno Sangro Carlos Gomez-Martin Manuel de la Mata Mercedes I?arrairaegui Elena Garralda Pilar Barrera Jose Ignacio Riezu-Boj Esther Larrea Carlos Alfaro Pablo Sarobe Juan José Lasarte Jose L. Pérez-Gracia Ignacio Melero Jesús Prieto | 2013 | Journal of Hepatology2013，，： | 6 |
| 2 | Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer:An update显示文摘The biosynthesis of prostanoids is involved in both physiological and pathological processes. The expression of prostaglandin-endoperoxide synthase 2(PTGS2; also known as COX-2) has been traditionally associated to the onset of several pathologies, from inflammation to cardiovascular, gastrointestinal and oncologic events. For this reason, the search of selective PTGS2 inhibitors has been a focus for therapeutic interventions. In addition to the classic non-steroidal anti-inflammatory drugs, selective and specific PTGS2 inhibitors, termed coxibs, have been generated and widely used. PTGS2 activity is less restrictive in terms of substrate specificity than the homeostatic counterpart PTGS1, and it accounts for the elevated prostanoid synthesis that accompanies several pathologies. The main regulation of PTGS2 occurs at the transcription level. In addition to this, the stability of the mRNA is finely regulated through the interaction with several cytoplasmic elements, ranging from specificmicroR NAs to proteins that control mR NA degradation. Moreover, the protein has been recognized to be the substrate for several post-translational modifications that affect both the enzyme activity and the targeting for degradation via proteasomal and non-proteasomal mechanisms. Among these modifications, phosphorylation, glycosylation and covalent modifications by reactive lipidic intermediates and by free radicals associated to the proinflammatory condition appear to be the main changes. Identification of these post-translational modifications is relevant to better understand the role of PTGS2 in several pathologies and to establish a correct analysis of the potential function of this protein in diseases progress. Finally, these modifications can be used as biomarkers to establish correlations with other parameters, including the immunomodulation dependent on molecular pathological epidemiology determinants, which may provide a better frame for potential therapeutic interventions. | Rafael I Jaén Patricia Prieto Marta Casado Paloma Martín-Sanz Lisardo Boscá | 2018 | World Journal of Gastroenterology2018，24，48： | 5 |
| 3 | Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort显示文摘BACKGROUND Colorectal cancer(CRC) is the second most common cause of cancer death worldwide. It is broadly described that cyclooxygenase-2(COX-2) is mainly overexpressed in CRC but less is known regarding post-translational modifications of this enzyme that may regulate its activity, intracellular localization and stability. Since metabolic and proteomic profile analysis is essential for cancer prognosis and diagnosis, our hypothesis is that the analysis of correlations between these specific parameters and COX-2 state in tumors of a high number of CRC patients could be useful for the understanding of the basis of this cancer in humans.AIM To analyze COX-2 regulation in colorectal cancer and to perform a detailed analysis of their metabolic and proteomic profile.METHODS Biopsies from both healthy and pathological colorectal tissues were taken under informed consent from patients during standard colonoscopy procedure in the University Hospital of Bellvitge(Barcelona, Spain) and Germans Trias i Pujol University Hospital(Campus Can Ruti)(Barcelona, Spain). Western blot analysis was used to determine COX-2 levels. Deglycosylation assays were performed in both cells and tumor samples incubating each sample with peptide N-glycosidase F(PNGase F). Prostaglandin E2(PGE2) levels were determined using a specific ELISA. 1 H high resolution magic angle spinning(HRMAS) analysis was performed using a Bruker AVIII 500 MHz spectrometer and proteomic analysis was performed in a nano-liquid chromatography-tandem mass spectrometer(nano LC-MS/MS) using a QExactive HF orbitrap MS.RESULTS Our data show that COX-2 has a differential expression profile in tumor tissue of CRC patients vs the adjacent non-tumor area, which correspond to a glycosylated and less active state of the protein. This fact was associated to a lesser PGE2 production in tumors. These results were corroborated in vitro performing deglycosylation assays in HT29 cell line where COX-2 protein profile was modified after PNGase F incubation, showing higher PGE2 levels. Moreover,HRMAS analysis indicated that tumor tissue has altered metabolic features vs non-tumor counterparts, presenting increased levels of certain metabolites such as taurine and phosphocholine and lower levels of lactate. In proteomic experiments, we detected an enlarged number of proteins in tumors that are mainly implicated in basic biological functions like mitochondrial activity,DNA/RNA processing, vesicular trafficking, metabolism, cytoskeleton and splicing.CONCLUSION In our colorectal cancer cohort, tumor tissue presents a differential COX-2 expression pattern with lower enzymatic activity that can be related to an altered metabolic and proteomic profile. | Patricia Prieto Rafael I Jaén Daniel Calle María Gómez-Serrano Estefanía Nú?ez María Fernández-Velasco Paloma Martín-Sanz Sergio Alonso Jesús Vázquez Sebastián Cerdán Miguel ángel Peinado Lisardo Boscá | 2019 | World Journal of Gastroenterology2019，25，4： | 4 |
| 4 | Endoscopic and anesthetic feasibility of EUS and ERCP combined in a single session versus two different sessions显示文摘AIM:To discuss the feasibility of single session endoscopic ultrasonography(EUS) to discuss and endoscopic retrograde cholangiopancreatography(ERCP) execution.METHODS:Retrospective endoscopic and anesthetic outcome comparison of performing both EUS and ERCP in a single endoscopic session(Group Ⅰ) versus performing each procedure in two different sessions(Group Ⅱ) was made.The following variables were evaluated:epidemiological variables,American Society of Anesthesiologists Physical Status Classification(ASA) level,procedural time,propofol dose,anesthetic complications,endoscopic complications and diagnostic yield,and therapeutic procedures on both groups.T-student,ChiSquare and Fisher test were used for comparison.RESULTS:We included 39 patients in Group Ⅰ(mean age:69.85 ± 9.25;27 men) and 46 in Group Ⅱ(mean age:67.46 ± 12.57;25 men).Procedural time did not differ significantly between both groups(Group Ⅰvs Group Ⅱ:93 ± 32.78 vs 98.98 ± 38.17;P >0.05) but the dose of propofol differed(Group Ⅰ vs Group Ⅱ:322.28 ± 250.54 mg vs 516.96 ± 289.06 mg;P = 0.001).Three patients had normal findings on both explorations.Three anesthetic complications [O2 desaturation(2),broncoaspiration(1)] and 9 endoscopic complications [pancreatitis(6),bleeding(1),perforation(1),cholangitis(1)] occurred without significant differences between both groups(P > 0.05).We did not find any significant difference regarding age,sex,ASA scale level,diagnostic yield or therapeutic maneuvers between both groups.CONCLUSION:The performance of EUS and ERCP in a single session offers a similar diagnostic and therapeutic yield,does not entail a higher complication risk and requires a significantly smaller dose of propofol for sedation compared with performing each exploration in a different session. | Juan J Vila Marcos Kutz Silvia Goi Miriam Ostiz Edurne Amorena Carlos Prieto Cristina Rodriguez Ignacio Fernández-Urien Francisco J Jiménez | 2011 | World Journal of Gastrointestinal Endoscopy2011，3，3： | 3 |
| 5 | Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure显示文摘Hepatitis B virus(HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma(HCC). During the last two decades, with the use of currently available anti-HBV therapies(lamivudine, entecavir and tenofovir disoproxil fumatate), there has been a decrease in the incidence of HBVassociated HCC(HBV-HCC). Furthermore, several studies have demonstrated a reduction in recurrent or new HCC development after initial HCC tumor ablation. However, during an observation period spanning 10 to 20 years, several case reports have demonstrated the development of new, subsequent new and recurrent HCC even in patients with undetectable serum HBV DNA. The persistent risk for HCC is attributed to the presence of covalently closed circular DNA(cccDNA) in the hepatocyte nucleus which continues to work as a template for HBV replication. While a functional cure(loss of hepatitis B surface antigen and undetectable viral DNA) can be attained with nucleos(t)ide analogues, these therapies do not eliminate cccDNA. Of utmost importance is successful eradication of the transcriptionally active HBV cccDNA from hepatocyte nuclei which would be considered a complete cure. The unpredictable nature of HCC development in patients with chronic HBV infection shows the need for a complete cure. Continued support and encouragement for research efforts aimed at developing curative therapies is imperative. The aims of this minireview are to highlight these observations and emphasize the need for a cure for HBV. | Brianna J Shinn Aaron Martin Robert M Coben Mitchell I Conn Jorge Prieto Howard Kroop Anthony J DiMarino Hie-Won Hann | 2019 | World Journal of Hepatology2019，11，1： | 3 |
| 6 | Nested PCR improves detection of infectious hematopoietic necrosis virus in cells coinfected with infectious pancreatic necrosis virus显示文摘 | Marta Alonso Sylvia Rodr??guez Sara I Pérez Prieto | 1999 | Journal of Virological Methods1999，，1： | 2 |
| 7 | Impairment of pre-mRNA splicing in liver disease: Mechanisms and consequences显示文摘Pre-mRNA splicing is an essential step in the process of gene expression in eukaryotes and consists of the removal ofintrons and the linking of exons to generate mature mRNAs. This is a highly regulated mechanism that allows the alternative usage of exons, the retention ofintronic sequences and the generation of exonic sequences of variable length. Most human genes undergo splicing events, and disruptions of this process have been associated with a variety of diseases, including cancer. Hepatocellular carcinoma (HCC) is a molecularly heterogeneous type of tumor that usually develops in a cirrhotic liver. Alterations in pre-mRNA splicing of some genes have been observed in liver cancer, and although still scarce, the available data suggest that splicing defects may have a role in hepatocarcinogenesis. Here we briefly review the general mechanisms that regulatepre-mRNA splicing, and discuss some examples that illustrate how this process is impaired in liver tumorigenesis, and may contribute to HCC development. We believe that a more thorough examination of pre-mRNA splicing is still needed to accurately draw the molecular portrait of liver cancer. This will surely contribute to a better understanding of the disease and to the development of new effective therapies. | Carmen Berasain Saioa Gońi Josefa Castillo Maria Ujue Latasa Jesús Prieto Matias A Avila | 2010 | World Journal of Gastroenterology2010，16，25： | 2 |
| 8 | Hysteroscopic hydrosalpinx occlusion with Essure device in IVF patients when salpingectomy or laparoscopy is contraindicated显示文摘 | Roberto Matorras Aintzane Rabanal Bego?a Prieto Santiago Diez I?aki Brouard Rosario Mendoza Antonia Exposito | 2013 | European Journal of Obstetrics and Gynecology2013，，1： | 2 |
| 9 | Isolation,purification,and characterization of a cold-active lipase from Aspergillus nidulans显示文摘 | Mayordomo I Randez-Gil F Prieto J A | 2000 | J Agric Food Chem2000，48，1： | 1 |
| 10 | Effects of dietary protein concentration on postweaning growth of Boer crossbred and Spanish goat wethers显示文摘 | PRIETO I GOETSCH A L BONSKALIEVA V | 2000 | Journal of Animal Science2000，78，9： | 1 |
| 11 | Transgenic sugarcane plants resistant to stem borer attack 显示文摘 | ARENCIBA A D VAZQUEZR I PRIETO D | 1997 | Molecular Breeding1997，，3： | 1 |
| 12 | Isolation, purification and characterization of a cold-active lipase from Aspergillus nidulans 显示文摘 | Mayordomo I Randez-Gil F Prieto J A | 2000 | J Agric Food Chem2000，48，： | 1 |
| 13 | Evaluation of an enzyme immunoassay technique for detection of antibodies against Treponema pallidum 显示文摘 | Castro R Prieto ES Santo I | 2003 | J Clin Microbiol2003，41，1： | 1 |
| 14 | Dynamic Capabilities and the Role of Organizational Knowledge: An Exploration 显示文摘 | Prieto I M Easterby - Smith M | 2006 | European Journal of Information Systems2006，15，5： | 1 |
| 15 | Bile duct ligation: step - by - step to cholangiocyte inflammatory tumorigenesis 显示文摘 | Aller MA Arias JL Prieto I | 2010 | Eur J Gastroenterol Hepatol2010，22，6： | 1 |
| 16 | Use of the Advia 120 hematology analyzer in the differential cytologic analysis of biological fluids (ce- rebrospinal, peritoneal,pleural, pericardial, synovial, and others) 显示文摘 | Aulesa C Mainar I Prieto M et ol | 2003 | Lab Hematol2003，9，4： | 1 |
| 17 | Accurate pedestrian indoor navigation by tightly coupling foot-mounted IMU and RFID measurements 显示文摘 | JIMENEZ R A R SECO G F PRIETO H I C | 2012 | IEEE Transactions on Instrumentation and Measurement2012，61，1： | 1 |
| 18 | Dynamic capabilities and knowledge management: An integrative role for learning 显示文摘 | Smith M E Prieto I M | 2008 | British Journal of Management2008，19，2： | 1 |
| 19 | Evaluation of an enzyme immunoassay technique for detection of antibodies against Treponema pallidum显示文摘 | Castro R Prieto ES Santo I | 2003 | J Clin Microbiol2003，41，1： | 1 |
| 20 | Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice 显示文摘 | ORTEGA S PRIETO I ODAJIMA J | 2003 | Nat Genet2003，35，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员